Clinical trial
Safety, Tolerability, PK and Efficacy of AZD1152 in Patients With Relapsed Acute…
NCT00497991 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00497991 |
|---|---|
| Title | Safety, Tolerability, PK and Efficacy of AZD1152 in Patients With Relapsed Acute Myeloid Leukemia |
| Official title | A Phase I/II, Open Label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of AZD1152 in Patients With Acute Myeloid Leukaemia. |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Myeloid Leukemia |
| Intervention type | Drug |
| Interventions | AZD1152 |
| Enrollment | 65 |
| Start date | May 1, 2006 |
| Primary completion | Oct 1, 2009 |
| Completion | Apr 1, 2010 |
| First posted | Jul 9, 2007 |
| Last update posted | Dec 8, 2010 |
| Countries | France, Italy, Netherlands, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: